CA2588445C - Pharmaceutical formulation containing a release rate controlling composition - Google Patents

Pharmaceutical formulation containing a release rate controlling composition Download PDF

Info

Publication number
CA2588445C
CA2588445C CA2588445A CA2588445A CA2588445C CA 2588445 C CA2588445 C CA 2588445C CA 2588445 A CA2588445 A CA 2588445A CA 2588445 A CA2588445 A CA 2588445A CA 2588445 C CA2588445 C CA 2588445C
Authority
CA
Canada
Prior art keywords
compound
range
employed
amount
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2588445A
Other languages
English (en)
French (fr)
Other versions
CA2588445A1 (en
Inventor
Nazaneen Pourkavoos
James R. Ney
Maria T. Cruanes
Yunhui Wu
Saurabh A. Palkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36118082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2588445(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2588445A1 publication Critical patent/CA2588445A1/en
Application granted granted Critical
Publication of CA2588445C publication Critical patent/CA2588445C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2588445A 2004-12-03 2005-12-02 Pharmaceutical formulation containing a release rate controlling composition Expired - Fee Related CA2588445C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63294404P 2004-12-03 2004-12-03
US60/632,944 2004-12-03
PCT/US2005/043727 WO2006060711A2 (en) 2004-12-03 2005-12-02 Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition

Publications (2)

Publication Number Publication Date
CA2588445A1 CA2588445A1 (en) 2006-06-08
CA2588445C true CA2588445C (en) 2013-06-25

Family

ID=36118082

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2588445A Expired - Fee Related CA2588445C (en) 2004-12-03 2005-12-02 Pharmaceutical formulation containing a release rate controlling composition

Country Status (16)

Country Link
US (1) US8852632B2 (enExample)
EP (2) EP1904067B2 (enExample)
JP (1) JP5228488B2 (enExample)
KR (1) KR101351059B1 (enExample)
CN (1) CN101068550B (enExample)
AU (1) AU2005311652B2 (enExample)
BR (1) BRPI0518781A2 (enExample)
CA (1) CA2588445C (enExample)
ES (1) ES2755273T3 (enExample)
IL (1) IL183615A (enExample)
MX (1) MX2007006635A (enExample)
NO (1) NO20073405L (enExample)
NZ (1) NZ555120A (enExample)
RU (1) RU2382648C2 (enExample)
WO (1) WO2006060711A2 (enExample)
ZA (1) ZA200703866B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1819323B2 (en) * 2004-12-03 2023-03-22 Merck Sharp & Dohme Corp. Pharmaceutical composition containing an anti-nucleating agent
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
KR20070085702A (ko) * 2004-12-03 2007-08-27 머크 앤드 캄파니 인코포레이티드 Ｕｇｔ1ａ1에 의해 대사된 약물의 약력학을 개선시키기위한 아타자나비르의 용도
US7687509B2 (en) 2007-07-09 2010-03-30 Concert Pharmaceuticals Inc. Pyrimidinecarboxamide derivatives
EP3970702A1 (en) 2009-10-26 2022-03-23 Merck Sharp & Dohme Corp. Solid pharmaceutical compositions containing an integrase inhibitor
CA2999435A1 (en) * 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
WO2012009446A1 (en) 2010-07-16 2012-01-19 Concert Pharmaceuticals Inc. Novel pyrimidinecarboxamide derivatives
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
EP2529741B1 (en) * 2011-06-01 2014-02-12 Ratiopharm GmbH Composition and Tablet Comprising Raltegravir
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
WO2014030172A2 (en) * 2012-08-23 2014-02-27 Hetero Research Foundation Pharmaceutical formulations of rufinamide
US9763934B2 (en) * 2014-03-05 2017-09-19 Professional Compounding Centers Of America Synergistic effect of poloxamer-based composition and itraconazole on fungus and yeast
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
CN108610338A (zh) * 2016-12-12 2018-10-02 天津国际生物医药联合研究院 一种嘧啶酮酰胺类化合物的制备方法
WO2019236395A1 (en) * 2018-06-06 2019-12-12 Merck Sharp & Dohme Corp. Formulations of raltegravir

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56992C2 (uk) * 1995-05-08 2003-06-16 Фармація Енд Апджон Компані <font face="Symbol">a</font>-ПІРИМІДИНТІОАЛКІЛЗАМІЩЕНІ ТА <font face="Symbol">a</font>-ПІРИМІДИНОКСОАЛКІЛЗАМІЩЕНІ СПОЛУКИ
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
MXPA02005291A (es) * 1999-12-03 2004-06-21 Polichem Sa Metodos para elaborar composiciones farmaceuticas de liberacion sostenida de alcaloides de cornezuelo de centeno que tienen biodisponibilidad mejorada y composiciones de los mismos.
CN1255185C (zh) * 2001-05-03 2006-05-10 弗·哈夫曼-拉罗切有限公司 无定形甲磺酸奈非那韦的药物剂型
SE0102887D0 (sv) * 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
US6673369B2 (en) * 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
CA2463976C (en) * 2001-10-26 2007-02-13 Benedetta Crescenzi N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
DK1441734T3 (da) * 2001-10-26 2007-06-11 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carboxamid-inhibitorer a HIV-integrase
WO2003086319A2 (en) * 2002-04-10 2003-10-23 Merck & Co., Inc. Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant
KR20050087865A (ko) 2002-12-27 2005-08-31 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티에스.피.에이. ＨＩＶ 인테그라제 억제제로서 유용한테트라하이드로-4Ｈ-피리도[1,2-ａ]피리미딘 및 관련화합물
ATE500819T1 (de) * 2003-12-31 2011-03-15 Bend Res Inc Stabilisierte pharmazeutische feste zusammensetzungen von arzneimitteln mit geringer löslichkeit, poloxameren und stabilisierenden polymeren
KR20070085702A (ko) 2004-12-03 2007-08-27 머크 앤드 캄파니 인코포레이티드 Ｕｇｔ1ａ1에 의해 대사된 약물의 약력학을 개선시키기위한 아타자나비르의 용도
EP1819323B2 (en) * 2004-12-03 2023-03-22 Merck Sharp & Dohme Corp. Pharmaceutical composition containing an anti-nucleating agent
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази

Also Published As

Publication number Publication date
RU2382648C2 (ru) 2010-02-27
EP1904067A2 (en) 2008-04-02
ZA200703866B (en) 2008-03-26
IL183615A0 (en) 2007-10-31
WO2006060711A3 (en) 2006-09-08
AU2005311652A1 (en) 2006-06-08
MX2007006635A (es) 2007-06-19
NO20073405L (no) 2007-07-02
RU2007125122A (ru) 2009-01-10
CN101068550A (zh) 2007-11-07
KR20070085695A (ko) 2007-08-27
CN101068550B (zh) 2011-03-30
NZ555120A (en) 2009-11-27
BRPI0518781A2 (pt) 2008-12-09
JP5228488B2 (ja) 2013-07-03
EP2586444B1 (en) 2019-09-25
EP1904067B1 (en) 2013-11-20
WO2006060711A2 (en) 2006-06-08
US8852632B2 (en) 2014-10-07
EP1904067B2 (en) 2017-10-11
IL183615A (en) 2013-01-31
US20070292504A1 (en) 2007-12-20
ES2755273T3 (es) 2020-04-22
KR101351059B1 (ko) 2014-02-17
JP2008521932A (ja) 2008-06-26
AU2005311652B2 (en) 2010-12-02
EP2586444A1 (en) 2013-05-01
CA2588445A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
ZA200703866B (en) Pharmaceutical formulation containing a release rate controlling compositions
JP2012184250A (ja) 抗核形成剤を含有する医薬組成物
WO2007087188A2 (en) Taste-masked tablets and granules
EP1849830B1 (en) Finely divided composition containing poorly water soluble substance
JP6123795B2 (ja) 放出制御医薬組成物
TW202435886A (zh) 米爾維仙(milvexian)醫藥組合物

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20171204